HWM
LPCN icon

HighMark Wealth Management’s Lipocine LPCN Stock Holding History

HighMark Wealth Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$803 – 583
2025
Q4 		$803 Buy
+100
New +$336 ﹤0.01% 519

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

HighMark Wealth Management's LPCN Position: Q1 2026 in Review

HighMark Wealth Management sold out of Lipocine (LPCN) in Q1 2026, closing a stake of 100 shares — an estimated $803 sold.

HighMark Wealth Management first reported a position in LPCN in Q4 2025 and held it in 1 quarter. The position peaked at $803 in Q4 2025. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • HighMark Wealth Management reported no remaining Lipocine position as of Q1 2026 after selling out during the quarter.
  • HighMark Wealth Management sold 100 Lipocine shares in Q1 2026, an estimated $803.
  • HighMark Wealth Management first reported a position in Lipocine in Q4 2025 and held it in 1 quarter.
  • HighMark Wealth Management's Lipocine position peaked at $803 in Q4 2025.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.